{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:14Z","timestamp":1791571754033,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-025-06240-1","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T05:13:10Z","timestamp":1739596390000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed \/ refractory multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Antoni","family":"Garcia-Gui\u00f1on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Andrea","family":"Charry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Sarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izarbe","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Segura de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santaliestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garcia-Pintos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Senin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8nia","family":"Abella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Granell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Seres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gironella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Alfons","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Marti-Tutusaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Ben Azaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"6240_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"6240_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","volume":"8","author":"SZ Usmani","year":"2018","unstructured":"Usmani SZ, Hoering A, Cavo M et al (2018) Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J 8:123. https:\/\/doi.org\/10.1038\/s41408-018-0155-7","journal-title":"Blood Cancer J"},{"key":"6240_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood.V130.Suppl_1.401.401","volume":"130","author":"M Cavo","year":"2017","unstructured":"Cavo M, Gay FM, Patriarca F et al (2017) Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02\/HO95 study. Blood 130:401. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.401.401","journal-title":"Blood"},{"key":"6240_CR4","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M et al (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7:e456\u2013e468. https:\/\/doi.org\/10.1016\/S2352-3026(20)30099-5","journal-title":"Lancet Haematol"},{"key":"6240_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C et al (2017) Lenalidomide, Bortezomib, and dexamethasone with transplantation for Myeloma. N Engl J Med 376:1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"6240_CR6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV et al (2020) Long-term Follow-Up results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in newly diagnosed multiple myeloma. J Clin Oncol off J Am Soc Clin Oncol 38:1928\u20131937. https:\/\/doi.org\/10.1200\/JCO.19.02515","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"6240_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"6240_CR8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R et al (2019) Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood 134:1337\u20131345. https:\/\/doi.org\/10.1182\/blood.2019000241","journal-title":"Blood"},{"key":"6240_CR9","doi-asserted-by":"publisher","first-page":"1197340","DOI":"10.3389\/fonc.2023.1197340","volume":"13","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Hebraud B, Oriol A et al (2023) Integrated analysis of randomized controlled trials evaluating bortezomib\u2009+\u2009lenalidomide\u2009+\u2009dexamethasone or bortezomib\u2009+\u2009thalidomide\u2009+\u2009dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma. Front Oncol 13:1197340. https:\/\/doi.org\/10.3389\/fonc.2023.1197340","journal-title":"Front Oncol"},{"key":"6240_CR10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M et al (2016) VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127:2569\u20132574. https:\/\/doi.org\/10.1182\/blood-2016-01-693580","journal-title":"Blood"},{"key":"6240_CR11","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2019.37.15_suppl.8003","volume":"37","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Phase 3 randomized study of daratumumab (DARA)\u2009+\u2009bortezomib\/thalidomide\/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. J Clin Oncol 37:8003\u20138003. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.8003","journal-title":"J Clin Oncol"},{"key":"6240_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"key":"6240_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab Therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"6240_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N et al (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 374:1621\u20131634. https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"key":"6240_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H et al (2018) Improvement in overall survival with Carfilzomib, Lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol off J Am Soc Clin Oncol 36:728\u2013734. https:\/\/doi.org\/10.1200\/JCO.2017.76.5032","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"6240_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA et al (2015) Carfilzomib, Lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142\u2013152. https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"6240_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327\u20131337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8","journal-title":"Lancet Oncol"},{"key":"6240_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","volume":"19","author":"RZ Orlowski","year":"2019","unstructured":"Orlowski RZ, Moreau P, Niesvizky R et al (2019) Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, Safety, and subgroups. Clin Lymphoma Myeloma Leuk 19:522\u2013530e1. https:\/\/doi.org\/10.1016\/j.clml.2019.04.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6240_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-020-04329-3","volume":"100","author":"A Mele","year":"2021","unstructured":"Mele A, Prete E, De Risi C et al (2021) Carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). Ann Hematol 100:429\u2013436. https:\/\/doi.org\/10.1007\/s00277-020-04329-3","journal-title":"Ann Hematol"},{"key":"6240_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2820","volume":"39","author":"S Rocchi","year":"2021","unstructured":"Rocchi S, Tacchetti P, Pantani L et al (2021) A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma. Hematol Oncol 39:41\u201350. https:\/\/doi.org\/10.1002\/hon.2820","journal-title":"Hematol Oncol"},{"key":"6240_CR21","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00277-020-04158-4","volume":"99","author":"S Palmieri","year":"2020","unstructured":"Palmieri S, Rocco S, Vitagliano O et al (2020) KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 99:2903\u20132909. https:\/\/doi.org\/10.1007\/s00277-020-04158-4","journal-title":"Ann Hematol"},{"key":"6240_CR22","doi-asserted-by":"publisher","first-page":"204062072211045","DOI":"10.1177\/20406207221104584","volume":"13","author":"Y Onda","year":"2022","unstructured":"Onda Y, Kanda J, Kaneko H et al (2022) Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol 13:20406207221104584. https:\/\/doi.org\/10.1177\/20406207221104584","journal-title":"Ther Adv Hematol"},{"key":"6240_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"6240_CR24","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for multiple myeloma: a Report from International Myeloma Working Group. J Clin Oncol off J Am Soc Clin Oncol 33:2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"6240_CR25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","volume":"23","author":"D-Y-L Chang-Chan","year":"2021","unstructured":"Chang-Chan D-Y-L, R\u00edos-Tamayo R, Rodr\u00edguez Barranco M et al (2021) Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 23:1429\u20131439. https:\/\/doi.org\/10.1007\/s12094-020-02541-1","journal-title":"Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"6240_CR26","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1111\/bjh.17237","volume":"192","author":"BA Derman","year":"2021","unstructured":"Derman BA, Langerman SS, Maric M et al (2021) Sex differences in outcomes in multiple myeloma. Br J Haematol 192:e66\u2013e69. https:\/\/doi.org\/10.1111\/bjh.17237","journal-title":"Br J Haematol"},{"key":"6240_CR27","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/leu.2017.122","volume":"31","author":"P Hari","year":"2017","unstructured":"Hari P, Mateos M-V, Abonour R et al (2017) Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia 31:2630\u20132641. https:\/\/doi.org\/10.1038\/leu.2017.122","journal-title":"Leukemia"},{"key":"6240_CR28","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"S Giralt","year":"2015","unstructured":"Giralt S, Garderet L, Durie B et al (2015) American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 21:2039\u20132051. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.016","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"6240_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K et al (2023) Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24:139\u2013150. https:\/\/doi.org\/10.1016\/S1470-2045(22)00738-0","journal-title":"Lancet Oncol"},{"key":"6240_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD et al (2020) Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:1317\u20131330. https:\/\/doi.org\/10.1016\/S1470-2045(20)30452-6","journal-title":"Lancet Oncol"},{"key":"6240_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","volume":"286","author":"S Bringhen","year":"2019","unstructured":"Bringhen S, Milan A, D\u2019Agostino M et al (2019) Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian society of arterial hypertension. J Intern Med 286:63\u201374. https:\/\/doi.org\/10.1111\/joim.12882","journal-title":"J Intern Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06240-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:24:36Z","timestamp":1743877476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6240"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06240-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CFL: Advisory boards: Janssen, BMS, Amgen, Pfizer, Sanofi, Beigene, GSK, Roche, Menarini; Honoraria: Amgen, Janssen, BMS, GSK, Sanofi, Pfizer, Beigene; Grants: BMS, Janssen, Amgen, GSK.EC: Advisory boards and honoraria: Janssen, Sanofi, GSK, Menarini, Amgen.CM: Advisory boards: Sanofi.YG: Janssen and Sanofi.The remaining co-authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}